Perrigo Company plc Amortization of Debt Discount (Premium)
Perrigo Company plc (PRGO) reported Amortization of Debt Discount (Premium) of $4.10 million for the 6-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-08-05
- Perrigo Company plc amortization of debt discount (premium) for the quarter ending 2026-06-27 was $1.90M, a 13.64% decline year-over-year.
- Perrigo Company plc amortization of debt discount (premium) for the quarter ending 2026-03-28 was $2.20M, a 0.00% change year-over-year.
- Perrigo Company plc amortization of debt discount (premium) for the quarter ending 2025-12-31 was $2.30M, a 70.51% decline year-over-year.
- Perrigo Company plc amortization of debt discount (premium) for the quarter ending 2025-09-27 was $2.30M, a 475.00% increase year-over-year.
- Perrigo Company plc amortization of debt discount (premium) for fiscal 2025 was $9.00M, a 1.12% increase from fiscal 2024.
- Perrigo Company plc amortization of debt discount (premium) for fiscal 2024 was $8.90M, a 286.96% increase from fiscal 2023.
- Perrigo Company plc amortization of debt discount (premium) for fiscal 2023 was $2.30M.
- Perrigo Company plc amortization of debt discount (premium) for fiscal 2022 was -$700.00K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2026-06-27 | $1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.10M 10-Q · filed 2026-08-05 | $6.40M derived: sum of 3 quarters · filed 2026-08-05 | $8.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | $2.20M 10-Q · filed 2026-05-06 | $4.50M derived: sum of 2 quarters · filed 2026-05-06 | $6.80M derived: sum of 3 quarters · filed 2026-05-06 | $9.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.60M derived: sum of 2 quarters · filed 2026-02-26 | $6.80M derived: sum of 3 quarters · filed 2026-08-05 | $9.00M 10-K · filed 2026-02-26 |
| 2025-09-27 | $2.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.50M derived: sum of 2 quarters · filed 2026-08-05 | $6.70M 10-Q · filed 2025-11-05 | $14.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-28 | $2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.40M 10-Q · filed 2026-08-05 | $12.20M derived: sum of 3 quarters · filed 2026-08-05 | $12.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-29 | $2.20M 10-Q · filed 2026-05-06 | $10.00M derived: sum of 2 quarters · filed 2026-05-06 | $10.40M derived: sum of 3 quarters · filed 2026-05-06 | $10.70M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $7.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.20M derived: sum of 2 quarters · filed 2026-02-26 | $8.50M derived: sum of 3 quarters · filed 2026-02-26 | $8.90M 10-K · filed 2026-02-26 |
| 2024-09-28 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $700.00K derived: sum of 2 quarters · filed 2025-11-05 | $1.10M 10-Q · filed 2025-11-05 | $1.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-29 | $300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $700.00K 10-Q · filed 2025-08-06 | $1.20M derived: sum of 3 quarters · filed 2026-02-26 | $1.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-30 | $400.00K 10-Q · filed 2025-05-07 | $900.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.30M derived: sum of 3 quarters · filed 2026-02-26 | $2.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $900.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.60M derived: sum of 3 quarters · filed 2026-02-26 | $2.30M 10-K · filed 2026-02-26 |
| 2023-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.10M derived: sum of 2 quarters · filed 2024-11-06 | $1.80M 10-Q · filed 2024-11-06 | $3.90M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-07-01 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $1.40M 10-Q · filed 2024-08-02 | $3.50M derived: sum of 3 quarters · filed 2025-02-28 | $5.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-04-01 | $700.00K 10-Q · filed 2024-05-07 | $2.80M derived: sum of 2 quarters · filed 2025-02-28 | $4.30M derived: sum of 3 quarters · filed 2025-02-28 | $200.00K derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $3.60M derived: sum of 2 quarters · filed 2025-02-28 | -$500.00K derived: sum of 3 quarters · filed 2025-02-28 | -$700.00K 10-K · filed 2025-02-28 |
| 2022-10-01 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$2.60M derived: sum of 2 quarters · filed 2023-11-07 | -$2.80M 10-Q · filed 2023-11-07 | -$3.90M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-07-02 | -$4.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$4.30M 10-Q · filed 2023-08-08 | -$5.40M derived: sum of 3 quarters · filed 2024-02-27 | -$6.70M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-04-02 | -$200.00K 10-Q · filed 2023-05-09 | -$1.30M derived: sum of 2 quarters · filed 2024-02-27 | -$2.60M derived: sum of 3 quarters · filed 2024-02-27 | -$3.30M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$2.40M derived: sum of 2 quarters · filed 2024-02-27 | -$3.10M derived: sum of 3 quarters · filed 2024-02-27 | -$3.80M 10-K · filed 2024-02-27 |
| 2021-10-02 | -$1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$2.00M derived: sum of 2 quarters · filed 2022-11-08 | -$2.70M 10-Q · filed 2022-11-08 | -$3.40M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-07-03 | -$700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$1.40M 10-Q · filed 2022-08-09 | -$2.10M derived: sum of 3 quarters · filed 2023-02-28 | -$2.50M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-04-03 | -$700.00K 10-Q · filed 2022-05-11 | -$1.40M derived: sum of 2 quarters · filed 2023-02-28 | -$1.80M derived: sum of 3 quarters · filed 2023-02-28 | -$2.40M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$1.10M derived: sum of 2 quarters · filed 2023-02-28 | -$1.70M derived: sum of 3 quarters · filed 2023-02-28 | -$2.40M 10-K · filed 2023-02-28 |
| 2020-09-26 | -$400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$1.00M derived: sum of 2 quarters · filed 2021-11-12 | -$1.70M 10-Q · filed 2021-11-12 | -$2.30M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-27 | -$600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$1.30M 10-Q · filed 2021-08-11 | -$1.90M derived: sum of 3 quarters · filed 2022-03-01 | -$2.70M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-28 | -$700.00K 10-Q · filed 2021-05-12 | -$1.30M derived: sum of 2 quarters · filed 2022-03-01 | -$2.10M derived: sum of 3 quarters · filed 2022-03-01 | -$3.20M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$1.40M derived: sum of 2 quarters · filed 2022-03-01 | -$2.50M derived: sum of 3 quarters · filed 2022-03-01 | -$4.40M 10-K · filed 2022-03-01 |
| 2019-09-28 | -$800.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$1.90M derived: sum of 2 quarters · filed 2020-11-05 | -$3.80M 10-Q · filed 2020-11-05 | -$5.70M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-29 | -$1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$3.00M 10-Q · filed 2020-08-05 | -$4.90M derived: sum of 3 quarters · filed 2021-03-01 | -$7.40M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-30 | -$1.90M 10-Q · filed 2020-05-05 | -$3.80M derived: sum of 2 quarters · filed 2021-03-01 | -$6.30M derived: sum of 3 quarters · filed 2021-03-01 | -$7.90M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$4.40M derived: sum of 2 quarters · filed 2021-03-01 | -$6.00M derived: sum of 3 quarters · filed 2021-03-01 | -$8.10M 10-K · filed 2021-03-01 |
| 2018-09-29 | -$2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$4.10M derived: sum of 2 quarters · filed 2019-11-06 | -$6.20M 10-Q · filed 2019-11-06 | -$10.20M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | -$1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$3.70M 10-Q · filed 2019-08-08 | -$7.70M derived: sum of 3 quarters · filed 2020-02-27 | -$14.30M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | -$2.10M 10-Q · filed 2019-05-09 | -$6.10M derived: sum of 2 quarters · filed 2020-02-27 | -$12.70M derived: sum of 3 quarters · filed 2020-02-27 | -$18.10M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | -$4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$10.60M derived: sum of 2 quarters · filed 2020-02-27 | -$16.00M derived: sum of 3 quarters · filed 2020-02-27 | -$22.40M 10-K · filed 2020-02-27 |
| 2017-09-30 | -$6.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$12.00M derived: sum of 2 quarters · filed 2018-11-08 | -$18.40M 10-Q · filed 2018-11-08 | |
| 2017-07-01 | -$5.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$11.80M 10-Q · filed 2018-08-09 | ||
| 2017-04-01 | -$6.40M 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | -$24.70M 10-K · filed 2019-02-27 | |||
| 2015-12-31 | -$10.20M 10-K · filed 2018-03-01 | |||
| 2015-06-27 | $200.00K 10-K · filed 2018-03-01 | |||
| 2014-06-28 | $2.00M 10-K · filed 2017-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |